Skip to main content

Table 1 Results of evaluation

From: Characterizing environmental and phenotypic associations using information theory and electronic health records

# Association of interest
MI ((95%CI)
Mediators for association of interest
MI (95%CI)
Result
*(D/I/E)
RS **
  RX-SX RX-DX DX-SX   
1 Metolazone-Shortness of Breath
0.086(0.075–0.097)
Metolazone-Hypertensive Disease 0.526(0.495–0.557) Hypertensive Disease-Shortness of Breath 0.132(0.113–0.152) I I
2 Metolazone-Headache
0.070(0.059–0.083)
Metolazone-Hypertensive Disease
0.526(0.495–0.557)
Hypertensive Disease-Headache
0.084(0.072–0.095)
E E
3 Metolazone-constipation
0.034 (0.023–0.046)
Metolazone-Hypertensive Disease
0.526(0.495–0.557)
Hypertensive Disease-constipation 0.019(0.009–0.028) E D
4 Rosiglitazone-Headache
0.079 (0.068–0.091)
Rosiglitazone-Diabetes
0.443(0.327–0.513)
Diabetes-Headache
0.117(0.093–0.128)
I D
5 Rosiglitazone-Chest Pain
0.077(0.069–0.088)
Rosiglitazone-Diabetes
0.443(0.327–0.513)
Diabetes-Chest Pain
0.090(0.074–0.115)
E E
  DX 1 - SX DX 1 - DX 2 DX 2 - SX   
6 Hypertensive Disease-Shortness of Breath 0.132(0.113–0.152) Hypertensive Disease-Heart Failure 0.651(0.563–0.738) Heart Failure-Shortness of Breath
0.173(0.158–0.186)
I I
7 Diabetes-Chest Pain
0.131(0.115–0.148)
Diabetes-Heart Failure
0.435(0.317–0.543)
Heart Failure-Chest Pain
0.184(0.169–0.193)
I I
  1. DX: Disease; RX: Drug; SX: Symptom; *I: Indirect association; D; Direct association; E: Either association; ** RS: Reference Standard.